Dyadic Q2 2024 revenue down 54% YoY to $386k; net loss $2.05M; cash $10.1M

DYADIC INTERNATIONAL INC

2025-Q2 EPS reported -$0.14 vs consensus -$0.06 ▼ miss (-128.8%)

Net loss $2.045M ($0.07/share) vs $2.153M ($0.07) YoY; operating loss $2.043M.
Cash and securities $10.1M at June 30, 2024, up from $7.3M at Dec 31, 2023.
Partnered with Proliant Health for animal-free recombinant albumin; $500k initial payment received.
Joint development with a Top 10 global dairy for food-grade alpha-lactalbumin.
Avian flu H5 nanoparticle antigen shows high neutralizing antibody titers in animal studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.